drugset / Trial / NCT06912529
Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This phase II study will evaluate the efficacy, safety and tolerability of second-line treatment with axicabtagene ciloleucel in primary mediastinal B-cell lymphoma patients (PMBCL).
Timeline
- Start
- 2025-03-13
- Primary completion
- 2025-07-25
- Completion
- 2025-07-25
Outcome
Outcome not reported
Stopped (Business): “Funder of the study terminated contract”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axicabtagene Ciloleucel | Cell therapy | — | Other |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |